Glasgow Precision Diagnostics and Therapeutics (P2D 2017)
Lead Research Organisation:
University of Glasgow
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills. The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers’ understanding of each other’s needs and capabilities. This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ‘entrepreneurs in residence’ schemes. Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.
Organisations
- University of Glasgow (Lead Research Organisation)
- Aptamer Group (Collaboration)
- Scottish Enterprise (Collaboration)
- Fujifilm (Japan) (Collaboration)
- FutuRx (Collaboration)
- AstraZeneca (Collaboration)
- Queen Elizabeth University Hospital (Collaboration)
- Panthera Biopartners (Collaboration)
- Portage Biotech Inc (Collaboration)
- BioTheryX (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- Glasgow Science Centre (Collaboration)
- GLASGOW CITY COUNCIL (Collaboration)
- Infimmune (Collaboration)
- Siemens Healthcare (Collaboration)
- Medical Research Scotland (Collaboration)
- Novartis (Collaboration)
- NHS Greater Glasgow and Clyde (NHSGGC) (Collaboration)
- Canon (Collaboration)
- Thermo Fisher Scientific (United Kingdom) (Collaboration)
- OracleBio (Collaboration)
- LifeArc (Collaboration)
- Kadans Science Partner (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- MR CoilTech Ltd (Collaboration)
- Plant Bioscience Limited Technology (Collaboration)
- BioClavis Ltd (Collaboration)
Publications
Biddau M
(2019)
Targeting the apicoplast in malaria.
in Biochemical Society transactions
Blair CM
(2019)
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.
in BMC cancer
Cabrero P
(2020)
Specialized stellate cells offer a privileged route for rapid water flux in Drosophila renal tubule.
in Proceedings of the National Academy of Sciences of the United States of America
Daly C
(2019)
Textbook of Vascular Medicine
Daly C
(2018)
The future of education? Using 3D animation and virtual reality in teaching physiology
in Physiology News
Daly C J
(2019)
From confocal microscope to virtual reality and computer games; technical and educational considerations
in Infocus Magazine
Daly CJ
(2019)
Examining Vascular Structure and Function Using Confocal Microscopy and 3D Imaging Techniques.
in Advances in experimental medicine and biology
Dickson-Murray E
(2021)
The Mia40/CHCHD4 oxidative folding system: Redox regulation and signalling in the mitochondrial intermembrane space
in Antioxidants
| Title | 3D models that can be used for research, teaching and public engagement |
| Description | The publication of 49 3D models that can be used for research, teaching and public engagement. |
| Type Of Art | Image |
| Year Produced | 2020 |
| Impact | Images used in Public Engagement Exhibition, 'Images on The Clyde.' |
| URL | https://sketchfab.com/GLS |
| Title | Market research for commercial development of a novel peptide tool for external payload delivery to mitochondria in cells |
| Description | A video of 15 min on the research, the interdisciplinary interactions of our team aiming at the general public, so that it can be used as a useful broadly available resource for outreach and awareness. |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2021 |
| Impact | Shared with the RSE, the Lily Foundation, the Glasgow School of Art, the Biochemical Society and other organisations that have a broad dissemination. |
| Description | Scientific adviser to Mitochondria Patient Organisations |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| URL | https://www.mymitomission.uk/ |
| Description | Ammar/Edwards/Lynch (INCISE): Investigating gene and protein differential expression in tubular, villous and tubulovillous adenomatous polyps at index colonoscopy and metachronous polyps to improve the bowel screening program |
| Amount | £99,580 (GBP) |
| Organisation | Beatson Cancer Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | BBSRC IAA University of Glasgow |
| Amount | £300,000 (GBP) |
| Funding ID | BB/S506734/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 03/2022 |
| Description | CRUK Programme Foundation Award - Vignir Helgason - letter of recommendation for funding stemming from Autophagy Conference collaboration |
| Amount | £1,345,574 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Development of a Novel Head Coil for Clinical Neuroimaging in 7 Tesla MRI Scanners |
| Amount | £663,609 (GBP) |
| Funding ID | 93468 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Dr Jennifer Hay (INCISE): Utilising AI for the detection of novel biomarkers in cancer |
| Amount | £139,787 (GBP) |
| Organisation | Beatson Cancer Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Excellence with Impact - 3D/VR models |
| Amount | £21,196 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 01/2020 |
| Description | Glasgow - Confidence in Concept 2019 |
| Amount | £450,000 (GBP) |
| Funding ID | MC_PC_19039 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 03/2023 |
| Description | Glasgow 2nd intake 2018 4-Year PhD Studentship (4th) Scheme: Mr Jack Beazer; Ms Emily Gallen; Mr Jithin Kuriakose; Ms Rebecca Rooney (4 years) |
| Amount | £612,156 (GBP) |
| Funding ID | FS/18/58/34179 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2022 |
| Description | Glasgow Precision Diagnostics and Therapeutics |
| Amount | £413,000 (GBP) |
| Funding ID | MC_PC_17160 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 09/2020 |
| Description | How do Redox regulators control apicoplast functions in the parasites causing toxoplasmosis and malaria |
| Amount | £333,614 (GBP) |
| Funding ID | MR/S024573/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2019 |
| End | 08/2020 |
| Description | INCISE consortium - UK Government Innovation Accelerator: Levelling Up Scheme award |
| Amount | £2,700,000 (GBP) |
| Organisation | Government of the UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 03/2026 |
| Description | Image based screening of aptamer libraries for novel immunomodulators |
| Amount | £69,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 10/2020 |
| Description | Integrated Technologies for Improved Polyp Surveillance (INCISE) |
| Amount | £2,349,971 (GBP) |
| Funding ID | 105858 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2020 |
| End | 04/2023 |
| Description | Investigating immunological prevention strategies for precursor lesions of colon cancer |
| Amount | £517,141 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 03/2027 |
| Description | Israel Innovation Authority (IIA) with FutuRx partners ( J&J, Takeda, Orbimed and Bayer) Seed Funding |
| Amount | $3,000,000 (USD) |
| Organisation | Israel Innovation Authority |
| Sector | Public |
| Country | Israel |
| Start | |
| Description | Lost in translation. Dissecting the divergent features of Toxoplasma gondii mitochondrial translation |
| Amount | £923,847 (GBP) |
| Funding ID | 217173/Z/19/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2019 |
| End | 08/2026 |
| Description | Market research analysis for diagnostics applications of the Mitotargin platform |
| Amount | £5,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 04/2022 |
| Description | Mitochondrial ROS mapping and control with sub-organellar resolution |
| Amount | £695,818 (GBP) |
| Funding ID | BB/T003804/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 01/2023 |
| Description | Mitotargin |
| Amount | £29,000 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2019 |
| End | 07/2020 |
| Description | Prof. George Baillie - Development of PDE4 PROTACS |
| Amount | £481,088 (GBP) |
| Organisation | BioTheryX |
| Sector | Private |
| Country | United States |
| Start | |
| Description | Redox regulation of protein functions in the plastid of Toxoplasma gondii |
| Amount | £333,615 (GBP) |
| Funding ID | MR/S024573/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 09/2022 |
| Description | Rescuing mitochondria in peril by targeting of a critical antioxidant protein |
| Amount | £490,257 (GBP) |
| Funding ID | BB/R009031/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 05/2021 |
| Description | Scottish Funding Council - Precision Medicine Scotland |
| Amount | £533,000 (GBP) |
| Organisation | Government of Scotland |
| Department | Scottish Funding Council |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | The Physiological Society - awarded to build virtual reality physiology game |
| Amount | £10,000 (GBP) |
| Organisation | Physiological Society |
| Sector | Charity/Non Profit |
| Country | Global |
| Start | |
| Description | The acceptability of post-polypectomy surveillance from the participant's perspective |
| Amount | £24,986 (GBP) |
| Organisation | Bowel Cancer UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Transgenic T. gondii as a platform for MeCP2 protein delivery to the CNS |
| Amount | £109,753 (GBP) |
| Funding ID | 3513 |
| Organisation | International Rett Syndrome Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 05/2018 |
| End | 05/2020 |
| Description | Translational Research Initiative |
| Amount | £450,000 (GBP) |
| Funding ID | MC_PC_18048 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2019 |
| End | 03/2022 |
| Description | UKRI The Strength in Places Fund (SiPF) |
| Amount | £38,000,000 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | University of Glasgow Wellcome Trust Translational Partnership |
| Amount | £800,000 (GBP) |
| Funding ID | 219390/Z/19/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 02/2023 |
| Title | multiplex immunofluorescence (mIF) staining for immune cell markers in human tissue |
| Description | As a result of this additional funding, the Edwards group has established multiplex immunofluorescence (mIF) staining for immune cell markers in human tissue. This technique was developed for the INCISE project, however, it has significant utility outside the project. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | This technique was developed for the INCISE project, however, it has significant utility outside the project. For example, Roxburgh's team has used mIF to detect and quantify immune cells in rectal cancer biopsies and Hatthakarnkul (PhD candidate, co-supervised by Edwards) has also used the mIF panel to examine the immune landscape in CRC tumour buds. |
| Title | Dataset of four key proteins involved in mitochondria biogenesis |
| Description | Dataset of four key proteins involved in mitochondria biogenesis (expression profiles) in over 300 cancer cell lines (in collaboration with EUROFINS). |
| Type Of Material | Database/Collection of data |
| Year Produced | 2022 |
| Provided To Others? | No |
| Impact | IP generated. |
| Description | "CRUSH": COVID-19 Drug-Screening and Resistance Hub |
| Organisation | LifeArc |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Participation in the UofG CVR Industry workshop aided the establishment of a formal partnership between the CVR and LifeArc to create CVR CRUSH, a drug-screening facility for pre-clinical evaluation of SARS-CoV-2 therapeutics. "CRUSH": COVID-19 Drug-Screening and Resistance Hub @ the MRC-University of Glasgow Centre for Virus Research, funded by LifeArc. |
| Collaborator Contribution | The UofG CVR Industry Workshop brought together CVR researchers and industry colleagues to begin knowledge exchange discussions. Through face-to-face interactions, we hope to improve CVR researchers' understanding of industry needs, and raise awareness of CVR research opportunities with our industry contacts. By improving understanding and raising awareness, aimed to encourage and support new collaborations. Participation in this workshop aided the establishment of a formal partnership between the CVR and LifeArc to create CVR CRUSH, a drug-screening facility for pre-clinical evaluation of SARS-CoV-2 therapeutics. |
| Impact | "CRUSH": COVID-19 Drug-Screening and Resistance Hub @ the MRC-University of Glasgow Centre for Virus Research. |
| Start Year | 2019 |
| Description | Aptamer Group in-kind contribution |
| Organisation | Aptamer Group |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Image based screening of aptamer libraries for novel immunomodulators. Dr. James Brewer's team expanded analysis of enriched aptamer pool. |
| Collaborator Contribution | Costs of aptamer synthesis and labelling have been subsidised by Aptamer Group as an in-kind contribution to the project. |
| Impact | Aptamer analysis pool expanded, toll receptor test completed, formulation optimised. |
| Start Year | 2019 |
| Description | Biotheryx funded an Industrial Placement PhD |
| Organisation | BioTheryX |
| Country | United States |
| Sector | Private |
| PI Contribution | Joint PhD student between Prof. George Baillie and BioTheryx (company collaboration). |
| Collaborator Contribution | £53,000 towards PhD studentship |
| Impact | PhD studentship for the project |
| Start Year | 2020 |
| Description | Enabling support for industry engagement events aligned with MVLS strategic research opportunities |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Creation of AstraZeneca hot-desk space at Clinical Innovation Zone |
| Collaborator Contribution | Utilisation of hot-desk space at Clinical Innovation Zone |
| Impact | In development |
| Start Year | 2019 |
| Description | Enabling support for industry engagement events aligned with MVLS strategic research opportunities |
| Organisation | Infimmune |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Provision of space for Infimmune Ltd within Clinical Innovation Zone |
| Collaborator Contribution | In development |
| Impact | In development |
| Start Year | 2020 |
| Description | Epeius Pharma |
| Organisation | FutuRx |
| Country | Israel |
| Sector | Private |
| PI Contribution | Founded based on the joint research efforts of Prof Oded Rechavi and Shahar Bracha (Tel Aviv University) and Wellcome Centre for Integrative Parasitology (WCIP) Senior lecturer and Research Fellow Dr Lilach Sheiner, Epeius Pharma develops next generation biological vehicles for delivery of therapeutic proteins into the central nervous system (CNS). |
| Collaborator Contribution | Founded based on the joint research efforts of Prof Oded Rechavi and Shahar Bracha (Tel Aviv University) and Wellcome Centre for Integrative Parasitology (WCIP) Senior lecturer and Research Fellow Dr Lilach Sheiner, Epeius Pharma develops next generation biological vehicles for delivery of therapeutic proteins into the central nervous system (CNS). |
| Impact | In development |
| Start Year | 2018 |
| Description | Glasgow Early Treatment Arm Favipiravir (GETAFIX) |
| Organisation | Fujifilm |
| Country | Japan |
| Sector | Private |
| PI Contribution | The UofG CVR Industry Workshop brought together CVR researchers and industry colleagues to begin knowledge exchange discussions. Through face-to-face interactions, we hope to improve CVR researchers' understanding of industry needs, and raise awareness of CVR research opportunities with our industry contacts. By improving understanding and raising awareness, we aim to encourage and support new collaborations. |
| Collaborator Contribution | As a direct result of this event, a formal collaboration was established between Dr Janet Scott and FUJIFILM Toyama Chemical Co., Ltd, underpinning the GETAFIX trial. |
| Impact | As a direct result of the UofG CVR Industry Workshop event, a formal collaboration was established between Dr Janet Scott and FUJIFILM Toyama Chemical Co., Ltd, underpinning the Glasgow Early Treatment Arm Favipiravir (GETAFIX) trial: a randomised controlled study of favipiravir in COVID-19 hospitalised patients. Funded by CSO, £156,510. |
| Start Year | 2019 |
| Description | GlaxoSmithKline Biologicals SA |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Dr. James Brewer cofunded IPP PhD student with GSK, looking at formulation of aluminium adjuvants and in vivo distribution studies. |
| Collaborator Contribution | GSK co funded studentship |
| Impact | Identification of aptamers with immune inhibitory activity and have preliminary data of the ability of aptamers to block T cell activation in vivo. |
| Start Year | 2019 |
| Description | INCISE Project |
| Organisation | BioClavis Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Enhanced project management support for integrated diagnostics. INCISE is a 3-year project, that utilises the latest advances in genomics, transcriptomics and digital pathology to develop a risk stratification tool, which will predict patient risk for developing future polyps. The MRC Proximity to Discovery funds have been used to support the immunohistochemistry (IHC) staining of polyp samples, specifically using the CD3 antibody to detect and quantify immune cell infiltrate (lymphocytes). |
| Collaborator Contribution | INCISE will significantly reduce the burden of endoscopy procedures on the NHS, through improvements in resource and finance requirements. NHS is collaborating with UofG group to transform bowel cancer screening in the UK by developing a tool that can predict which patients with pre-cancerous growths in their bowels, called polyps, will develop further polyps or cancer. Canon Safe Haven AI Platform (SHAIP) used to integrate and validate the prototype AI algorithms in a live clinical setting. - Leveraging both the physical and intellectual resources of the INCISE collaboration, the University of Glasgow and BioClavis have secured over £120,000 in funding from Medical Research Scotland is support a 4-year PhD studentship. The PhD project will examine the role of the gut microbiome in influencing the risk of future colorectal polyps. |
| Impact | 10.1101/2020.08.16.20175935 Total investment from partners and UofG £1.1M. Project made possible with further £2.3M for funding from Innovate UK. Breakdown from the £1.1M: £197k BioClavis £296k Canon Medical Europe £67k OracleBio £540 University of Glasgow |
| Start Year | 2019 |
| Description | INCISE Project |
| Organisation | Canon |
| Department | Canon Medical Research Europe |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Enhanced project management support for integrated diagnostics. INCISE is a 3-year project, that utilises the latest advances in genomics, transcriptomics and digital pathology to develop a risk stratification tool, which will predict patient risk for developing future polyps. The MRC Proximity to Discovery funds have been used to support the immunohistochemistry (IHC) staining of polyp samples, specifically using the CD3 antibody to detect and quantify immune cell infiltrate (lymphocytes). |
| Collaborator Contribution | INCISE will significantly reduce the burden of endoscopy procedures on the NHS, through improvements in resource and finance requirements. NHS is collaborating with UofG group to transform bowel cancer screening in the UK by developing a tool that can predict which patients with pre-cancerous growths in their bowels, called polyps, will develop further polyps or cancer. Canon Safe Haven AI Platform (SHAIP) used to integrate and validate the prototype AI algorithms in a live clinical setting. - Leveraging both the physical and intellectual resources of the INCISE collaboration, the University of Glasgow and BioClavis have secured over £120,000 in funding from Medical Research Scotland is support a 4-year PhD studentship. The PhD project will examine the role of the gut microbiome in influencing the risk of future colorectal polyps. |
| Impact | 10.1101/2020.08.16.20175935 Total investment from partners and UofG £1.1M. Project made possible with further £2.3M for funding from Innovate UK. Breakdown from the £1.1M: £197k BioClavis £296k Canon Medical Europe £67k OracleBio £540 University of Glasgow |
| Start Year | 2019 |
| Description | INCISE Project |
| Organisation | Medical Research Scotland |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Enhanced project management support for integrated diagnostics. INCISE is a 3-year project, that utilises the latest advances in genomics, transcriptomics and digital pathology to develop a risk stratification tool, which will predict patient risk for developing future polyps. The MRC Proximity to Discovery funds have been used to support the immunohistochemistry (IHC) staining of polyp samples, specifically using the CD3 antibody to detect and quantify immune cell infiltrate (lymphocytes). |
| Collaborator Contribution | INCISE will significantly reduce the burden of endoscopy procedures on the NHS, through improvements in resource and finance requirements. NHS is collaborating with UofG group to transform bowel cancer screening in the UK by developing a tool that can predict which patients with pre-cancerous growths in their bowels, called polyps, will develop further polyps or cancer. Canon Safe Haven AI Platform (SHAIP) used to integrate and validate the prototype AI algorithms in a live clinical setting. - Leveraging both the physical and intellectual resources of the INCISE collaboration, the University of Glasgow and BioClavis have secured over £120,000 in funding from Medical Research Scotland is support a 4-year PhD studentship. The PhD project will examine the role of the gut microbiome in influencing the risk of future colorectal polyps. |
| Impact | 10.1101/2020.08.16.20175935 Total investment from partners and UofG £1.1M. Project made possible with further £2.3M for funding from Innovate UK. Breakdown from the £1.1M: £197k BioClavis £296k Canon Medical Europe £67k OracleBio £540 University of Glasgow |
| Start Year | 2019 |
| Description | INCISE Project |
| Organisation | NHS Greater Glasgow and Clyde (NHSGGC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Enhanced project management support for integrated diagnostics. INCISE is a 3-year project, that utilises the latest advances in genomics, transcriptomics and digital pathology to develop a risk stratification tool, which will predict patient risk for developing future polyps. The MRC Proximity to Discovery funds have been used to support the immunohistochemistry (IHC) staining of polyp samples, specifically using the CD3 antibody to detect and quantify immune cell infiltrate (lymphocytes). |
| Collaborator Contribution | INCISE will significantly reduce the burden of endoscopy procedures on the NHS, through improvements in resource and finance requirements. NHS is collaborating with UofG group to transform bowel cancer screening in the UK by developing a tool that can predict which patients with pre-cancerous growths in their bowels, called polyps, will develop further polyps or cancer. Canon Safe Haven AI Platform (SHAIP) used to integrate and validate the prototype AI algorithms in a live clinical setting. - Leveraging both the physical and intellectual resources of the INCISE collaboration, the University of Glasgow and BioClavis have secured over £120,000 in funding from Medical Research Scotland is support a 4-year PhD studentship. The PhD project will examine the role of the gut microbiome in influencing the risk of future colorectal polyps. |
| Impact | 10.1101/2020.08.16.20175935 Total investment from partners and UofG £1.1M. Project made possible with further £2.3M for funding from Innovate UK. Breakdown from the £1.1M: £197k BioClavis £296k Canon Medical Europe £67k OracleBio £540 University of Glasgow |
| Start Year | 2019 |
| Description | INCISE Project |
| Organisation | OracleBio |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Enhanced project management support for integrated diagnostics. INCISE is a 3-year project, that utilises the latest advances in genomics, transcriptomics and digital pathology to develop a risk stratification tool, which will predict patient risk for developing future polyps. The MRC Proximity to Discovery funds have been used to support the immunohistochemistry (IHC) staining of polyp samples, specifically using the CD3 antibody to detect and quantify immune cell infiltrate (lymphocytes). |
| Collaborator Contribution | INCISE will significantly reduce the burden of endoscopy procedures on the NHS, through improvements in resource and finance requirements. NHS is collaborating with UofG group to transform bowel cancer screening in the UK by developing a tool that can predict which patients with pre-cancerous growths in their bowels, called polyps, will develop further polyps or cancer. Canon Safe Haven AI Platform (SHAIP) used to integrate and validate the prototype AI algorithms in a live clinical setting. - Leveraging both the physical and intellectual resources of the INCISE collaboration, the University of Glasgow and BioClavis have secured over £120,000 in funding from Medical Research Scotland is support a 4-year PhD studentship. The PhD project will examine the role of the gut microbiome in influencing the risk of future colorectal polyps. |
| Impact | 10.1101/2020.08.16.20175935 Total investment from partners and UofG £1.1M. Project made possible with further £2.3M for funding from Innovate UK. Breakdown from the £1.1M: £197k BioClavis £296k Canon Medical Europe £67k OracleBio £540 University of Glasgow |
| Start Year | 2019 |
| Description | LifeArc - V. Helgason - Combining TKI Treatment with Novel Autophagy Inhibitor (MRT403) for Eradication of Leukaemic Stem Cells |
| Organisation | LifeArc |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | To test the effect of lead ULK1 inhibitor (MRT403) on survival of leukaemic stem cells using pre-clinical models of Chronic Myeloid Leukaemia. Extra £15k was provided by Helgason to buy mice, when the breeding capacity was restricted due to Covid19 restrictions. |
| Collaborator Contribution | LifeArc supplied the ULK1 inhibitors for the studies. LifeArc undertook manufacture of sufficient quantities of compounds and PK studies to confirm the kinetics and suitability of the compounds for use in humans. LifeArc also provided on-going support in the study with regard to drug development and analysis. |
| Impact | LifeArc licenced the ULK1 Programme to a Company. The Company has approached Helgason and setup a "Sponsored Collaborative Agreement" for the value of £317,392. This will support the appointment of a Research Assistant/Associate. |
| Start Year | 2019 |
| Description | LifeArc - V. Helgason - Combining TKI Treatment with Novel Autophagy Inhibitor (MRT403) for Eradication of Leukaemic Stem Cells |
| Organisation | University of Glasgow |
| Department | Institute of Cancer Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | To test the effect of lead ULK1 inhibitor (MRT403) on survival of leukaemic stem cells using pre-clinical models of Chronic Myeloid Leukaemia. Extra £15k was provided by Helgason to buy mice, when the breeding capacity was restricted due to Covid19 restrictions. |
| Collaborator Contribution | LifeArc supplied the ULK1 inhibitors for the studies. LifeArc undertook manufacture of sufficient quantities of compounds and PK studies to confirm the kinetics and suitability of the compounds for use in humans. LifeArc also provided on-going support in the study with regard to drug development and analysis. |
| Impact | LifeArc licenced the ULK1 Programme to a Company. The Company has approached Helgason and setup a "Sponsored Collaborative Agreement" for the value of £317,392. This will support the appointment of a Research Assistant/Associate. |
| Start Year | 2019 |
| Description | Novartis - Copeland |
| Organisation | Novartis |
| Country | Global |
| Sector | Private |
| PI Contribution | Progressing in project entitled 'Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)' |
| Collaborator Contribution | Collaboration for CML project |
| Impact | N/A |
| Start Year | 2019 |
| Description | Plant Biosciences Ltd - UofG Christie |
| Organisation | Plant Bioscience Limited Technology |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Dr. J. Christie patent WO2020169973A1 |
| Collaborator Contribution | License use to Plant Biosciences Ltd |
| Impact | Patent WO2020169973A1 and license to Plant Biosciences Ltd |
| Start Year | 2020 |
| Description | Plant Biosciences Ltd - UofG Tokatlidis and Milner |
| Organisation | Plant Bioscience Limited Technology |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Prof. Tokatlidis and Dr. Milner BBSRC FoF funded project |
| Collaborator Contribution | Collaboration with PBL to further project Bacteriocins as a seed treatment: A novel method for protecting plants against bacterial pathogens. |
| Impact | BBSRC FoF funding |
| Start Year | 2019 |
| Description | Portage Glasgow Ltd |
| Organisation | Portage Biotech Inc |
| Country | Virgin Islands, British |
| Sector | Private |
| PI Contribution | Proximity to Discovery is the reason that Portage Glasgow Ltd (PGL) was formed by Portage Pharmaceuticals Ltd and the Univ. of Glasgow. Agreements precipitant to formation of the company, including license agreements were completed and are the bases of PGL. This stemmed from a Portage Glasgow lead compound in cancer or autoimmune diseases - development and publication strategy. Target selection in Treg cell pathways to produce a tumor immunity potentiator and a review of progress various receptor targets. |
| Collaborator Contribution | Developing a joint venture with Portage Pharmaceuticals Ltd (PPL): staff visit/exchange. Juvenesecnce has acquired Portage as of 2022. |
| Impact | Paper: 10.1186/s12885-019-5489-4 2 PhD studentships (Portage funded), PhD student, Connor Blair who worked on this project won "Young Innovator of the year" in a national competition. Patents: 130268-8001.US00, 130268-8002.US00 |
| Start Year | 2018 |
| Description | Strength in Places - Health Innovation Hub, Living Lab programme related partnerships |
| Organisation | BioClavis Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | In June 2020, Alok Sharma, secretary of state for Business, Energy and Industrial Strategy announced a UKRI award of £38M to the " The Living Laboratory: driving economic growth in Glasgow through real world implementation of precision medicine" lead by Glasgow University. This award validated Glasgow's UK leadership in Precision Medicine and included funding of £18M towards the Health Innovation Hub (HIH) the main focus of this P2D support. The Glasgow entry, built upon the proven and successful "triple helix" model. It built a wide ranging consortium of Academia, NHS and Industry partners and was strongly supported by City of Glasgow. The proposal was submitted in September 2019, results announced in June 2020 with official start date October 1st. The £38M SIPF Living award is the biggest single grant awarded to Glasgow University. This successful submission was preceded by an intense period bid preparation partly supported by P2D. The preparation included market research, evidence gathering, industry and NHS outreach, scientific economic and infrastructure planning in an 12-18 month period prior to submission. The P2D funding played an important part in supporting the development of what was ultimately a successful funding bid. This P2D support was instrumental in delivering all of the original HIH related objectives. P2D support also made an important additional contribution to the economic case for UKRI investment in the Living Laboratory. This project engaged different stakeholders to establish: • The barriers to growth for existing PM SMEs and start-ups (e.g. proof of concept funding, growth finance, R&D innovation support, skills support) • Scale and nature of demand from SMEs and start-ups for the Health Innovation Hub - type and size of office and lab space; type of incubation and innovation support etc • Expand on work carried out as part of the SIA to capture requirements of potential inward investors on the QEUHH campus and the 'Living Lab' proposition - what would make the QEUH campus more attractive for them to invest, what type of facilities would they be looking for? • With support from Scottish Enterprise, the group had undertaken options appraisal of sites for the Health Innovation Hub. One option has already been identified but we wish to explore other possibilities, and also try to leverage further funding for the Hub. This feedback will be collected through in-depth meetings and telephone interviews with 30-40 key stakeholders and businesses, supplemented by an online survey to capture feedback from a wide range of sectors with an interest in PM. |
| Collaborator Contribution | UKRI £38m under SIPF call £22M from consortium partners (£7M Cash £15M in kind) Additional support £31m (City Deal; GSC) funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. |
| Impact | This exercise was successfully carried out via a series of in depth interview with industry NHS and Key Opinion Leaders by SQW consultants. The results of this survey validated the evidence of demand for Precision Medicine investment gained in the preceding Science and Innovation Audit. This timely updated evidence demand was an important part of the successful proposal in particular by making the case for the new HIH building. Specialists in design and development of science parks in the UK and Europe was engaged to address these issues. Their contribution directly supported by P2D was crucial to developing a first pass high level description of infrastructure need, identifying specific gaps in terms of office space and working with City of Glasgow and NHS to evaluate and identify the eventual site for the Living Lab. This work also made the case for a high level specification of accommodation which helped attract matching funding from Kadans. In addition, it played a central role in introducing and maintaining the relationship with the Kadans group the major infrastructure development partner. Kadans interest and investment in the Living Laboratory proposal has been critical to leveraging the £18M UKRI funding in the immediate future and as a longer-term investment partner. It also leveraged £31M City deal funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. In 2021/22, expansion of MR Coiltech - current CIZ tenant and Living Laboratory partner organisation, expanding from academic lab and hot desk to take on an additional commercial lab. |
| Start Year | 2020 |
| Description | Strength in Places - Health Innovation Hub, Living Lab programme related partnerships |
| Organisation | Canon |
| Department | Canon Medical Research Europe |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | In June 2020, Alok Sharma, secretary of state for Business, Energy and Industrial Strategy announced a UKRI award of £38M to the " The Living Laboratory: driving economic growth in Glasgow through real world implementation of precision medicine" lead by Glasgow University. This award validated Glasgow's UK leadership in Precision Medicine and included funding of £18M towards the Health Innovation Hub (HIH) the main focus of this P2D support. The Glasgow entry, built upon the proven and successful "triple helix" model. It built a wide ranging consortium of Academia, NHS and Industry partners and was strongly supported by City of Glasgow. The proposal was submitted in September 2019, results announced in June 2020 with official start date October 1st. The £38M SIPF Living award is the biggest single grant awarded to Glasgow University. This successful submission was preceded by an intense period bid preparation partly supported by P2D. The preparation included market research, evidence gathering, industry and NHS outreach, scientific economic and infrastructure planning in an 12-18 month period prior to submission. The P2D funding played an important part in supporting the development of what was ultimately a successful funding bid. This P2D support was instrumental in delivering all of the original HIH related objectives. P2D support also made an important additional contribution to the economic case for UKRI investment in the Living Laboratory. This project engaged different stakeholders to establish: • The barriers to growth for existing PM SMEs and start-ups (e.g. proof of concept funding, growth finance, R&D innovation support, skills support) • Scale and nature of demand from SMEs and start-ups for the Health Innovation Hub - type and size of office and lab space; type of incubation and innovation support etc • Expand on work carried out as part of the SIA to capture requirements of potential inward investors on the QEUHH campus and the 'Living Lab' proposition - what would make the QEUH campus more attractive for them to invest, what type of facilities would they be looking for? • With support from Scottish Enterprise, the group had undertaken options appraisal of sites for the Health Innovation Hub. One option has already been identified but we wish to explore other possibilities, and also try to leverage further funding for the Hub. This feedback will be collected through in-depth meetings and telephone interviews with 30-40 key stakeholders and businesses, supplemented by an online survey to capture feedback from a wide range of sectors with an interest in PM. |
| Collaborator Contribution | UKRI £38m under SIPF call £22M from consortium partners (£7M Cash £15M in kind) Additional support £31m (City Deal; GSC) funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. |
| Impact | This exercise was successfully carried out via a series of in depth interview with industry NHS and Key Opinion Leaders by SQW consultants. The results of this survey validated the evidence of demand for Precision Medicine investment gained in the preceding Science and Innovation Audit. This timely updated evidence demand was an important part of the successful proposal in particular by making the case for the new HIH building. Specialists in design and development of science parks in the UK and Europe was engaged to address these issues. Their contribution directly supported by P2D was crucial to developing a first pass high level description of infrastructure need, identifying specific gaps in terms of office space and working with City of Glasgow and NHS to evaluate and identify the eventual site for the Living Lab. This work also made the case for a high level specification of accommodation which helped attract matching funding from Kadans. In addition, it played a central role in introducing and maintaining the relationship with the Kadans group the major infrastructure development partner. Kadans interest and investment in the Living Laboratory proposal has been critical to leveraging the £18M UKRI funding in the immediate future and as a longer-term investment partner. It also leveraged £31M City deal funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. In 2021/22, expansion of MR Coiltech - current CIZ tenant and Living Laboratory partner organisation, expanding from academic lab and hot desk to take on an additional commercial lab. |
| Start Year | 2020 |
| Description | Strength in Places - Health Innovation Hub, Living Lab programme related partnerships |
| Organisation | Glasgow City Council |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | In June 2020, Alok Sharma, secretary of state for Business, Energy and Industrial Strategy announced a UKRI award of £38M to the " The Living Laboratory: driving economic growth in Glasgow through real world implementation of precision medicine" lead by Glasgow University. This award validated Glasgow's UK leadership in Precision Medicine and included funding of £18M towards the Health Innovation Hub (HIH) the main focus of this P2D support. The Glasgow entry, built upon the proven and successful "triple helix" model. It built a wide ranging consortium of Academia, NHS and Industry partners and was strongly supported by City of Glasgow. The proposal was submitted in September 2019, results announced in June 2020 with official start date October 1st. The £38M SIPF Living award is the biggest single grant awarded to Glasgow University. This successful submission was preceded by an intense period bid preparation partly supported by P2D. The preparation included market research, evidence gathering, industry and NHS outreach, scientific economic and infrastructure planning in an 12-18 month period prior to submission. The P2D funding played an important part in supporting the development of what was ultimately a successful funding bid. This P2D support was instrumental in delivering all of the original HIH related objectives. P2D support also made an important additional contribution to the economic case for UKRI investment in the Living Laboratory. This project engaged different stakeholders to establish: • The barriers to growth for existing PM SMEs and start-ups (e.g. proof of concept funding, growth finance, R&D innovation support, skills support) • Scale and nature of demand from SMEs and start-ups for the Health Innovation Hub - type and size of office and lab space; type of incubation and innovation support etc • Expand on work carried out as part of the SIA to capture requirements of potential inward investors on the QEUHH campus and the 'Living Lab' proposition - what would make the QEUH campus more attractive for them to invest, what type of facilities would they be looking for? • With support from Scottish Enterprise, the group had undertaken options appraisal of sites for the Health Innovation Hub. One option has already been identified but we wish to explore other possibilities, and also try to leverage further funding for the Hub. This feedback will be collected through in-depth meetings and telephone interviews with 30-40 key stakeholders and businesses, supplemented by an online survey to capture feedback from a wide range of sectors with an interest in PM. |
| Collaborator Contribution | UKRI £38m under SIPF call £22M from consortium partners (£7M Cash £15M in kind) Additional support £31m (City Deal; GSC) funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. |
| Impact | This exercise was successfully carried out via a series of in depth interview with industry NHS and Key Opinion Leaders by SQW consultants. The results of this survey validated the evidence of demand for Precision Medicine investment gained in the preceding Science and Innovation Audit. This timely updated evidence demand was an important part of the successful proposal in particular by making the case for the new HIH building. Specialists in design and development of science parks in the UK and Europe was engaged to address these issues. Their contribution directly supported by P2D was crucial to developing a first pass high level description of infrastructure need, identifying specific gaps in terms of office space and working with City of Glasgow and NHS to evaluate and identify the eventual site for the Living Lab. This work also made the case for a high level specification of accommodation which helped attract matching funding from Kadans. In addition, it played a central role in introducing and maintaining the relationship with the Kadans group the major infrastructure development partner. Kadans interest and investment in the Living Laboratory proposal has been critical to leveraging the £18M UKRI funding in the immediate future and as a longer-term investment partner. It also leveraged £31M City deal funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. In 2021/22, expansion of MR Coiltech - current CIZ tenant and Living Laboratory partner organisation, expanding from academic lab and hot desk to take on an additional commercial lab. |
| Start Year | 2020 |
| Description | Strength in Places - Health Innovation Hub, Living Lab programme related partnerships |
| Organisation | Glasgow Science Centre |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | In June 2020, Alok Sharma, secretary of state for Business, Energy and Industrial Strategy announced a UKRI award of £38M to the " The Living Laboratory: driving economic growth in Glasgow through real world implementation of precision medicine" lead by Glasgow University. This award validated Glasgow's UK leadership in Precision Medicine and included funding of £18M towards the Health Innovation Hub (HIH) the main focus of this P2D support. The Glasgow entry, built upon the proven and successful "triple helix" model. It built a wide ranging consortium of Academia, NHS and Industry partners and was strongly supported by City of Glasgow. The proposal was submitted in September 2019, results announced in June 2020 with official start date October 1st. The £38M SIPF Living award is the biggest single grant awarded to Glasgow University. This successful submission was preceded by an intense period bid preparation partly supported by P2D. The preparation included market research, evidence gathering, industry and NHS outreach, scientific economic and infrastructure planning in an 12-18 month period prior to submission. The P2D funding played an important part in supporting the development of what was ultimately a successful funding bid. This P2D support was instrumental in delivering all of the original HIH related objectives. P2D support also made an important additional contribution to the economic case for UKRI investment in the Living Laboratory. This project engaged different stakeholders to establish: • The barriers to growth for existing PM SMEs and start-ups (e.g. proof of concept funding, growth finance, R&D innovation support, skills support) • Scale and nature of demand from SMEs and start-ups for the Health Innovation Hub - type and size of office and lab space; type of incubation and innovation support etc • Expand on work carried out as part of the SIA to capture requirements of potential inward investors on the QEUHH campus and the 'Living Lab' proposition - what would make the QEUH campus more attractive for them to invest, what type of facilities would they be looking for? • With support from Scottish Enterprise, the group had undertaken options appraisal of sites for the Health Innovation Hub. One option has already been identified but we wish to explore other possibilities, and also try to leverage further funding for the Hub. This feedback will be collected through in-depth meetings and telephone interviews with 30-40 key stakeholders and businesses, supplemented by an online survey to capture feedback from a wide range of sectors with an interest in PM. |
| Collaborator Contribution | UKRI £38m under SIPF call £22M from consortium partners (£7M Cash £15M in kind) Additional support £31m (City Deal; GSC) funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. |
| Impact | This exercise was successfully carried out via a series of in depth interview with industry NHS and Key Opinion Leaders by SQW consultants. The results of this survey validated the evidence of demand for Precision Medicine investment gained in the preceding Science and Innovation Audit. This timely updated evidence demand was an important part of the successful proposal in particular by making the case for the new HIH building. Specialists in design and development of science parks in the UK and Europe was engaged to address these issues. Their contribution directly supported by P2D was crucial to developing a first pass high level description of infrastructure need, identifying specific gaps in terms of office space and working with City of Glasgow and NHS to evaluate and identify the eventual site for the Living Lab. This work also made the case for a high level specification of accommodation which helped attract matching funding from Kadans. In addition, it played a central role in introducing and maintaining the relationship with the Kadans group the major infrastructure development partner. Kadans interest and investment in the Living Laboratory proposal has been critical to leveraging the £18M UKRI funding in the immediate future and as a longer-term investment partner. It also leveraged £31M City deal funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. In 2021/22, expansion of MR Coiltech - current CIZ tenant and Living Laboratory partner organisation, expanding from academic lab and hot desk to take on an additional commercial lab. |
| Start Year | 2020 |
| Description | Strength in Places - Health Innovation Hub, Living Lab programme related partnerships |
| Organisation | Kadans Science Partner |
| Country | Netherlands |
| Sector | Private |
| PI Contribution | In June 2020, Alok Sharma, secretary of state for Business, Energy and Industrial Strategy announced a UKRI award of £38M to the " The Living Laboratory: driving economic growth in Glasgow through real world implementation of precision medicine" lead by Glasgow University. This award validated Glasgow's UK leadership in Precision Medicine and included funding of £18M towards the Health Innovation Hub (HIH) the main focus of this P2D support. The Glasgow entry, built upon the proven and successful "triple helix" model. It built a wide ranging consortium of Academia, NHS and Industry partners and was strongly supported by City of Glasgow. The proposal was submitted in September 2019, results announced in June 2020 with official start date October 1st. The £38M SIPF Living award is the biggest single grant awarded to Glasgow University. This successful submission was preceded by an intense period bid preparation partly supported by P2D. The preparation included market research, evidence gathering, industry and NHS outreach, scientific economic and infrastructure planning in an 12-18 month period prior to submission. The P2D funding played an important part in supporting the development of what was ultimately a successful funding bid. This P2D support was instrumental in delivering all of the original HIH related objectives. P2D support also made an important additional contribution to the economic case for UKRI investment in the Living Laboratory. This project engaged different stakeholders to establish: • The barriers to growth for existing PM SMEs and start-ups (e.g. proof of concept funding, growth finance, R&D innovation support, skills support) • Scale and nature of demand from SMEs and start-ups for the Health Innovation Hub - type and size of office and lab space; type of incubation and innovation support etc • Expand on work carried out as part of the SIA to capture requirements of potential inward investors on the QEUHH campus and the 'Living Lab' proposition - what would make the QEUH campus more attractive for them to invest, what type of facilities would they be looking for? • With support from Scottish Enterprise, the group had undertaken options appraisal of sites for the Health Innovation Hub. One option has already been identified but we wish to explore other possibilities, and also try to leverage further funding for the Hub. This feedback will be collected through in-depth meetings and telephone interviews with 30-40 key stakeholders and businesses, supplemented by an online survey to capture feedback from a wide range of sectors with an interest in PM. |
| Collaborator Contribution | UKRI £38m under SIPF call £22M from consortium partners (£7M Cash £15M in kind) Additional support £31m (City Deal; GSC) funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. |
| Impact | This exercise was successfully carried out via a series of in depth interview with industry NHS and Key Opinion Leaders by SQW consultants. The results of this survey validated the evidence of demand for Precision Medicine investment gained in the preceding Science and Innovation Audit. This timely updated evidence demand was an important part of the successful proposal in particular by making the case for the new HIH building. Specialists in design and development of science parks in the UK and Europe was engaged to address these issues. Their contribution directly supported by P2D was crucial to developing a first pass high level description of infrastructure need, identifying specific gaps in terms of office space and working with City of Glasgow and NHS to evaluate and identify the eventual site for the Living Lab. This work also made the case for a high level specification of accommodation which helped attract matching funding from Kadans. In addition, it played a central role in introducing and maintaining the relationship with the Kadans group the major infrastructure development partner. Kadans interest and investment in the Living Laboratory proposal has been critical to leveraging the £18M UKRI funding in the immediate future and as a longer-term investment partner. It also leveraged £31M City deal funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. In 2021/22, expansion of MR Coiltech - current CIZ tenant and Living Laboratory partner organisation, expanding from academic lab and hot desk to take on an additional commercial lab. |
| Start Year | 2020 |
| Description | Strength in Places - Health Innovation Hub, Living Lab programme related partnerships |
| Organisation | MR CoilTech Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | In June 2020, Alok Sharma, secretary of state for Business, Energy and Industrial Strategy announced a UKRI award of £38M to the " The Living Laboratory: driving economic growth in Glasgow through real world implementation of precision medicine" lead by Glasgow University. This award validated Glasgow's UK leadership in Precision Medicine and included funding of £18M towards the Health Innovation Hub (HIH) the main focus of this P2D support. The Glasgow entry, built upon the proven and successful "triple helix" model. It built a wide ranging consortium of Academia, NHS and Industry partners and was strongly supported by City of Glasgow. The proposal was submitted in September 2019, results announced in June 2020 with official start date October 1st. The £38M SIPF Living award is the biggest single grant awarded to Glasgow University. This successful submission was preceded by an intense period bid preparation partly supported by P2D. The preparation included market research, evidence gathering, industry and NHS outreach, scientific economic and infrastructure planning in an 12-18 month period prior to submission. The P2D funding played an important part in supporting the development of what was ultimately a successful funding bid. This P2D support was instrumental in delivering all of the original HIH related objectives. P2D support also made an important additional contribution to the economic case for UKRI investment in the Living Laboratory. This project engaged different stakeholders to establish: • The barriers to growth for existing PM SMEs and start-ups (e.g. proof of concept funding, growth finance, R&D innovation support, skills support) • Scale and nature of demand from SMEs and start-ups for the Health Innovation Hub - type and size of office and lab space; type of incubation and innovation support etc • Expand on work carried out as part of the SIA to capture requirements of potential inward investors on the QEUHH campus and the 'Living Lab' proposition - what would make the QEUH campus more attractive for them to invest, what type of facilities would they be looking for? • With support from Scottish Enterprise, the group had undertaken options appraisal of sites for the Health Innovation Hub. One option has already been identified but we wish to explore other possibilities, and also try to leverage further funding for the Hub. This feedback will be collected through in-depth meetings and telephone interviews with 30-40 key stakeholders and businesses, supplemented by an online survey to capture feedback from a wide range of sectors with an interest in PM. |
| Collaborator Contribution | UKRI £38m under SIPF call £22M from consortium partners (£7M Cash £15M in kind) Additional support £31m (City Deal; GSC) funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. |
| Impact | This exercise was successfully carried out via a series of in depth interview with industry NHS and Key Opinion Leaders by SQW consultants. The results of this survey validated the evidence of demand for Precision Medicine investment gained in the preceding Science and Innovation Audit. This timely updated evidence demand was an important part of the successful proposal in particular by making the case for the new HIH building. Specialists in design and development of science parks in the UK and Europe was engaged to address these issues. Their contribution directly supported by P2D was crucial to developing a first pass high level description of infrastructure need, identifying specific gaps in terms of office space and working with City of Glasgow and NHS to evaluate and identify the eventual site for the Living Lab. This work also made the case for a high level specification of accommodation which helped attract matching funding from Kadans. In addition, it played a central role in introducing and maintaining the relationship with the Kadans group the major infrastructure development partner. Kadans interest and investment in the Living Laboratory proposal has been critical to leveraging the £18M UKRI funding in the immediate future and as a longer-term investment partner. It also leveraged £31M City deal funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. In 2021/22, expansion of MR Coiltech - current CIZ tenant and Living Laboratory partner organisation, expanding from academic lab and hot desk to take on an additional commercial lab. |
| Start Year | 2020 |
| Description | Strength in Places - Health Innovation Hub, Living Lab programme related partnerships |
| Organisation | Panthera Biopartners |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | In June 2020, Alok Sharma, secretary of state for Business, Energy and Industrial Strategy announced a UKRI award of £38M to the " The Living Laboratory: driving economic growth in Glasgow through real world implementation of precision medicine" lead by Glasgow University. This award validated Glasgow's UK leadership in Precision Medicine and included funding of £18M towards the Health Innovation Hub (HIH) the main focus of this P2D support. The Glasgow entry, built upon the proven and successful "triple helix" model. It built a wide ranging consortium of Academia, NHS and Industry partners and was strongly supported by City of Glasgow. The proposal was submitted in September 2019, results announced in June 2020 with official start date October 1st. The £38M SIPF Living award is the biggest single grant awarded to Glasgow University. This successful submission was preceded by an intense period bid preparation partly supported by P2D. The preparation included market research, evidence gathering, industry and NHS outreach, scientific economic and infrastructure planning in an 12-18 month period prior to submission. The P2D funding played an important part in supporting the development of what was ultimately a successful funding bid. This P2D support was instrumental in delivering all of the original HIH related objectives. P2D support also made an important additional contribution to the economic case for UKRI investment in the Living Laboratory. This project engaged different stakeholders to establish: • The barriers to growth for existing PM SMEs and start-ups (e.g. proof of concept funding, growth finance, R&D innovation support, skills support) • Scale and nature of demand from SMEs and start-ups for the Health Innovation Hub - type and size of office and lab space; type of incubation and innovation support etc • Expand on work carried out as part of the SIA to capture requirements of potential inward investors on the QEUHH campus and the 'Living Lab' proposition - what would make the QEUH campus more attractive for them to invest, what type of facilities would they be looking for? • With support from Scottish Enterprise, the group had undertaken options appraisal of sites for the Health Innovation Hub. One option has already been identified but we wish to explore other possibilities, and also try to leverage further funding for the Hub. This feedback will be collected through in-depth meetings and telephone interviews with 30-40 key stakeholders and businesses, supplemented by an online survey to capture feedback from a wide range of sectors with an interest in PM. |
| Collaborator Contribution | UKRI £38m under SIPF call £22M from consortium partners (£7M Cash £15M in kind) Additional support £31m (City Deal; GSC) funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. |
| Impact | This exercise was successfully carried out via a series of in depth interview with industry NHS and Key Opinion Leaders by SQW consultants. The results of this survey validated the evidence of demand for Precision Medicine investment gained in the preceding Science and Innovation Audit. This timely updated evidence demand was an important part of the successful proposal in particular by making the case for the new HIH building. Specialists in design and development of science parks in the UK and Europe was engaged to address these issues. Their contribution directly supported by P2D was crucial to developing a first pass high level description of infrastructure need, identifying specific gaps in terms of office space and working with City of Glasgow and NHS to evaluate and identify the eventual site for the Living Lab. This work also made the case for a high level specification of accommodation which helped attract matching funding from Kadans. In addition, it played a central role in introducing and maintaining the relationship with the Kadans group the major infrastructure development partner. Kadans interest and investment in the Living Laboratory proposal has been critical to leveraging the £18M UKRI funding in the immediate future and as a longer-term investment partner. It also leveraged £31M City deal funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. In 2021/22, expansion of MR Coiltech - current CIZ tenant and Living Laboratory partner organisation, expanding from academic lab and hot desk to take on an additional commercial lab. |
| Start Year | 2020 |
| Description | Strength in Places - Health Innovation Hub, Living Lab programme related partnerships |
| Organisation | Queen Elizabeth University Hospital |
| Department | Precision Medicine Scotland Innovation Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | In June 2020, Alok Sharma, secretary of state for Business, Energy and Industrial Strategy announced a UKRI award of £38M to the " The Living Laboratory: driving economic growth in Glasgow through real world implementation of precision medicine" lead by Glasgow University. This award validated Glasgow's UK leadership in Precision Medicine and included funding of £18M towards the Health Innovation Hub (HIH) the main focus of this P2D support. The Glasgow entry, built upon the proven and successful "triple helix" model. It built a wide ranging consortium of Academia, NHS and Industry partners and was strongly supported by City of Glasgow. The proposal was submitted in September 2019, results announced in June 2020 with official start date October 1st. The £38M SIPF Living award is the biggest single grant awarded to Glasgow University. This successful submission was preceded by an intense period bid preparation partly supported by P2D. The preparation included market research, evidence gathering, industry and NHS outreach, scientific economic and infrastructure planning in an 12-18 month period prior to submission. The P2D funding played an important part in supporting the development of what was ultimately a successful funding bid. This P2D support was instrumental in delivering all of the original HIH related objectives. P2D support also made an important additional contribution to the economic case for UKRI investment in the Living Laboratory. This project engaged different stakeholders to establish: • The barriers to growth for existing PM SMEs and start-ups (e.g. proof of concept funding, growth finance, R&D innovation support, skills support) • Scale and nature of demand from SMEs and start-ups for the Health Innovation Hub - type and size of office and lab space; type of incubation and innovation support etc • Expand on work carried out as part of the SIA to capture requirements of potential inward investors on the QEUHH campus and the 'Living Lab' proposition - what would make the QEUH campus more attractive for them to invest, what type of facilities would they be looking for? • With support from Scottish Enterprise, the group had undertaken options appraisal of sites for the Health Innovation Hub. One option has already been identified but we wish to explore other possibilities, and also try to leverage further funding for the Hub. This feedback will be collected through in-depth meetings and telephone interviews with 30-40 key stakeholders and businesses, supplemented by an online survey to capture feedback from a wide range of sectors with an interest in PM. |
| Collaborator Contribution | UKRI £38m under SIPF call £22M from consortium partners (£7M Cash £15M in kind) Additional support £31m (City Deal; GSC) funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. |
| Impact | This exercise was successfully carried out via a series of in depth interview with industry NHS and Key Opinion Leaders by SQW consultants. The results of this survey validated the evidence of demand for Precision Medicine investment gained in the preceding Science and Innovation Audit. This timely updated evidence demand was an important part of the successful proposal in particular by making the case for the new HIH building. Specialists in design and development of science parks in the UK and Europe was engaged to address these issues. Their contribution directly supported by P2D was crucial to developing a first pass high level description of infrastructure need, identifying specific gaps in terms of office space and working with City of Glasgow and NHS to evaluate and identify the eventual site for the Living Lab. This work also made the case for a high level specification of accommodation which helped attract matching funding from Kadans. In addition, it played a central role in introducing and maintaining the relationship with the Kadans group the major infrastructure development partner. Kadans interest and investment in the Living Laboratory proposal has been critical to leveraging the £18M UKRI funding in the immediate future and as a longer-term investment partner. It also leveraged £31M City deal funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. In 2021/22, expansion of MR Coiltech - current CIZ tenant and Living Laboratory partner organisation, expanding from academic lab and hot desk to take on an additional commercial lab. |
| Start Year | 2020 |
| Description | Strength in Places - Health Innovation Hub, Living Lab programme related partnerships |
| Organisation | Scottish Enterprise |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | In June 2020, Alok Sharma, secretary of state for Business, Energy and Industrial Strategy announced a UKRI award of £38M to the " The Living Laboratory: driving economic growth in Glasgow through real world implementation of precision medicine" lead by Glasgow University. This award validated Glasgow's UK leadership in Precision Medicine and included funding of £18M towards the Health Innovation Hub (HIH) the main focus of this P2D support. The Glasgow entry, built upon the proven and successful "triple helix" model. It built a wide ranging consortium of Academia, NHS and Industry partners and was strongly supported by City of Glasgow. The proposal was submitted in September 2019, results announced in June 2020 with official start date October 1st. The £38M SIPF Living award is the biggest single grant awarded to Glasgow University. This successful submission was preceded by an intense period bid preparation partly supported by P2D. The preparation included market research, evidence gathering, industry and NHS outreach, scientific economic and infrastructure planning in an 12-18 month period prior to submission. The P2D funding played an important part in supporting the development of what was ultimately a successful funding bid. This P2D support was instrumental in delivering all of the original HIH related objectives. P2D support also made an important additional contribution to the economic case for UKRI investment in the Living Laboratory. This project engaged different stakeholders to establish: • The barriers to growth for existing PM SMEs and start-ups (e.g. proof of concept funding, growth finance, R&D innovation support, skills support) • Scale and nature of demand from SMEs and start-ups for the Health Innovation Hub - type and size of office and lab space; type of incubation and innovation support etc • Expand on work carried out as part of the SIA to capture requirements of potential inward investors on the QEUHH campus and the 'Living Lab' proposition - what would make the QEUH campus more attractive for them to invest, what type of facilities would they be looking for? • With support from Scottish Enterprise, the group had undertaken options appraisal of sites for the Health Innovation Hub. One option has already been identified but we wish to explore other possibilities, and also try to leverage further funding for the Hub. This feedback will be collected through in-depth meetings and telephone interviews with 30-40 key stakeholders and businesses, supplemented by an online survey to capture feedback from a wide range of sectors with an interest in PM. |
| Collaborator Contribution | UKRI £38m under SIPF call £22M from consortium partners (£7M Cash £15M in kind) Additional support £31m (City Deal; GSC) funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. |
| Impact | This exercise was successfully carried out via a series of in depth interview with industry NHS and Key Opinion Leaders by SQW consultants. The results of this survey validated the evidence of demand for Precision Medicine investment gained in the preceding Science and Innovation Audit. This timely updated evidence demand was an important part of the successful proposal in particular by making the case for the new HIH building. Specialists in design and development of science parks in the UK and Europe was engaged to address these issues. Their contribution directly supported by P2D was crucial to developing a first pass high level description of infrastructure need, identifying specific gaps in terms of office space and working with City of Glasgow and NHS to evaluate and identify the eventual site for the Living Lab. This work also made the case for a high level specification of accommodation which helped attract matching funding from Kadans. In addition, it played a central role in introducing and maintaining the relationship with the Kadans group the major infrastructure development partner. Kadans interest and investment in the Living Laboratory proposal has been critical to leveraging the £18M UKRI funding in the immediate future and as a longer-term investment partner. It also leveraged £31M City deal funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. In 2021/22, expansion of MR Coiltech - current CIZ tenant and Living Laboratory partner organisation, expanding from academic lab and hot desk to take on an additional commercial lab. |
| Start Year | 2020 |
| Description | Strength in Places - Health Innovation Hub, Living Lab programme related partnerships |
| Organisation | Siemens Healthcare |
| Country | Germany |
| Sector | Private |
| PI Contribution | In June 2020, Alok Sharma, secretary of state for Business, Energy and Industrial Strategy announced a UKRI award of £38M to the " The Living Laboratory: driving economic growth in Glasgow through real world implementation of precision medicine" lead by Glasgow University. This award validated Glasgow's UK leadership in Precision Medicine and included funding of £18M towards the Health Innovation Hub (HIH) the main focus of this P2D support. The Glasgow entry, built upon the proven and successful "triple helix" model. It built a wide ranging consortium of Academia, NHS and Industry partners and was strongly supported by City of Glasgow. The proposal was submitted in September 2019, results announced in June 2020 with official start date October 1st. The £38M SIPF Living award is the biggest single grant awarded to Glasgow University. This successful submission was preceded by an intense period bid preparation partly supported by P2D. The preparation included market research, evidence gathering, industry and NHS outreach, scientific economic and infrastructure planning in an 12-18 month period prior to submission. The P2D funding played an important part in supporting the development of what was ultimately a successful funding bid. This P2D support was instrumental in delivering all of the original HIH related objectives. P2D support also made an important additional contribution to the economic case for UKRI investment in the Living Laboratory. This project engaged different stakeholders to establish: • The barriers to growth for existing PM SMEs and start-ups (e.g. proof of concept funding, growth finance, R&D innovation support, skills support) • Scale and nature of demand from SMEs and start-ups for the Health Innovation Hub - type and size of office and lab space; type of incubation and innovation support etc • Expand on work carried out as part of the SIA to capture requirements of potential inward investors on the QEUHH campus and the 'Living Lab' proposition - what would make the QEUH campus more attractive for them to invest, what type of facilities would they be looking for? • With support from Scottish Enterprise, the group had undertaken options appraisal of sites for the Health Innovation Hub. One option has already been identified but we wish to explore other possibilities, and also try to leverage further funding for the Hub. This feedback will be collected through in-depth meetings and telephone interviews with 30-40 key stakeholders and businesses, supplemented by an online survey to capture feedback from a wide range of sectors with an interest in PM. |
| Collaborator Contribution | UKRI £38m under SIPF call £22M from consortium partners (£7M Cash £15M in kind) Additional support £31m (City Deal; GSC) funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. |
| Impact | This exercise was successfully carried out via a series of in depth interview with industry NHS and Key Opinion Leaders by SQW consultants. The results of this survey validated the evidence of demand for Precision Medicine investment gained in the preceding Science and Innovation Audit. This timely updated evidence demand was an important part of the successful proposal in particular by making the case for the new HIH building. Specialists in design and development of science parks in the UK and Europe was engaged to address these issues. Their contribution directly supported by P2D was crucial to developing a first pass high level description of infrastructure need, identifying specific gaps in terms of office space and working with City of Glasgow and NHS to evaluate and identify the eventual site for the Living Lab. This work also made the case for a high level specification of accommodation which helped attract matching funding from Kadans. In addition, it played a central role in introducing and maintaining the relationship with the Kadans group the major infrastructure development partner. Kadans interest and investment in the Living Laboratory proposal has been critical to leveraging the £18M UKRI funding in the immediate future and as a longer-term investment partner. It also leveraged £31M City deal funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. In 2021/22, expansion of MR Coiltech - current CIZ tenant and Living Laboratory partner organisation, expanding from academic lab and hot desk to take on an additional commercial lab. |
| Start Year | 2020 |
| Description | Strength in Places - Health Innovation Hub, Living Lab programme related partnerships |
| Organisation | Thermo Fisher Scientific |
| Country | United States |
| Sector | Private |
| PI Contribution | In June 2020, Alok Sharma, secretary of state for Business, Energy and Industrial Strategy announced a UKRI award of £38M to the " The Living Laboratory: driving economic growth in Glasgow through real world implementation of precision medicine" lead by Glasgow University. This award validated Glasgow's UK leadership in Precision Medicine and included funding of £18M towards the Health Innovation Hub (HIH) the main focus of this P2D support. The Glasgow entry, built upon the proven and successful "triple helix" model. It built a wide ranging consortium of Academia, NHS and Industry partners and was strongly supported by City of Glasgow. The proposal was submitted in September 2019, results announced in June 2020 with official start date October 1st. The £38M SIPF Living award is the biggest single grant awarded to Glasgow University. This successful submission was preceded by an intense period bid preparation partly supported by P2D. The preparation included market research, evidence gathering, industry and NHS outreach, scientific economic and infrastructure planning in an 12-18 month period prior to submission. The P2D funding played an important part in supporting the development of what was ultimately a successful funding bid. This P2D support was instrumental in delivering all of the original HIH related objectives. P2D support also made an important additional contribution to the economic case for UKRI investment in the Living Laboratory. This project engaged different stakeholders to establish: • The barriers to growth for existing PM SMEs and start-ups (e.g. proof of concept funding, growth finance, R&D innovation support, skills support) • Scale and nature of demand from SMEs and start-ups for the Health Innovation Hub - type and size of office and lab space; type of incubation and innovation support etc • Expand on work carried out as part of the SIA to capture requirements of potential inward investors on the QEUHH campus and the 'Living Lab' proposition - what would make the QEUH campus more attractive for them to invest, what type of facilities would they be looking for? • With support from Scottish Enterprise, the group had undertaken options appraisal of sites for the Health Innovation Hub. One option has already been identified but we wish to explore other possibilities, and also try to leverage further funding for the Hub. This feedback will be collected through in-depth meetings and telephone interviews with 30-40 key stakeholders and businesses, supplemented by an online survey to capture feedback from a wide range of sectors with an interest in PM. |
| Collaborator Contribution | UKRI £38m under SIPF call £22M from consortium partners (£7M Cash £15M in kind) Additional support £31m (City Deal; GSC) funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. |
| Impact | This exercise was successfully carried out via a series of in depth interview with industry NHS and Key Opinion Leaders by SQW consultants. The results of this survey validated the evidence of demand for Precision Medicine investment gained in the preceding Science and Innovation Audit. This timely updated evidence demand was an important part of the successful proposal in particular by making the case for the new HIH building. Specialists in design and development of science parks in the UK and Europe was engaged to address these issues. Their contribution directly supported by P2D was crucial to developing a first pass high level description of infrastructure need, identifying specific gaps in terms of office space and working with City of Glasgow and NHS to evaluate and identify the eventual site for the Living Lab. This work also made the case for a high level specification of accommodation which helped attract matching funding from Kadans. In addition, it played a central role in introducing and maintaining the relationship with the Kadans group the major infrastructure development partner. Kadans interest and investment in the Living Laboratory proposal has been critical to leveraging the £18M UKRI funding in the immediate future and as a longer-term investment partner. It also leveraged £31M City deal funding for the and essential improvements to the site access and environment opening up the brown field site on which the HIH will be located. In 2021/22, expansion of MR Coiltech - current CIZ tenant and Living Laboratory partner organisation, expanding from academic lab and hot desk to take on an additional commercial lab. |
| Start Year | 2020 |
| Description | UKRI's Strength in Places Fund (SIPF) - The Living Lab |
| Organisation | Kadans Science Partner |
| Country | Netherlands |
| Sector | Private |
| PI Contribution | Bid for UKRI Strength in Places Fund. The Precision Medicine "Living Lab" project will strengthen Glasgow's ecosystem by establishing new innovation pathways in a real-world clinical setting and a dedicated Health Innovation Hub that offers grow-on space and enabling "soft" infrastructures. This was identified as a major opportunity in both the University-led BEIS Science and Innovation Audit published earlier this month, as well as by a major summit of national and international experts brought together by the First Minister at Scotland's Precision Medicine Summit last year. |
| Collaborator Contribution | Partner on bid for UKRI Strength in Places Fund |
| Impact | Bid for UKRI Strength in Places Fund advanced to final stage (decision expected April 2020). £50k of seedcorn funding awarded by UKRI to take the plans to the next stage. |
| Start Year | 2019 |
| Description | University of Glasgow's Reinvigorating Research fund |
| Organisation | University of Glasgow |
| Department | Glasgow Precision Oncology Laboratory |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Secured an additional £39.5K in funding from the University of Glasgow's Reinvigorating Research fund. |
| Collaborator Contribution | This funding will support sequencing of 96 future polyp samples using the Glasgow Precision Oncology Laboratory's Cancer Plus Panel. Mutational profiles future polyps will be compared with the corresponding index polyp. |
| Impact | N/A |
| Start Year | 2021 |
| Title | Engineered parasites for delivering protein to the central nervous system (cns) |
| Description | Provided are nucleic acid constructs, Toxoplasma comprising same, pharmaceutical compositions comprising same and methods using same for delivering a protein-of-interest to a tissue-of-interest of a subject, such as the CNS and further treating a pathology which is treatable by administration of a therapeutic polypeptide in a central nervous system of the subject. |
| IP Reference | US20200121731A1 |
| Protection | Patent application published |
| Year Protection Granted | 2020 |
| Licensed | Yes |
| Impact | The biotech accelerator FutuRx is licensing the patent |
| Title | INSECT CONTROL AGENTS |
| Description | The invention relates to CAP2b analogues having activity against hemipteran insects such as aphids, and their use as insect control agents (e.g. insecticides) and plant protection agents. In particular it has been found that a known CAP2b analogue designated 1895, and new CAP2b analogues including molecules designated 2129, 2315, 2316 and 2320, have activity against hemipteran insects and so find use for control of hemipteran insects and plant protection. |
| IP Reference | WO2020115076 |
| Protection | Patent application published |
| Year Protection Granted | 2020 |
| Licensed | Commercial In Confidence |
| Impact | Spin out company, SOLASTA Bio formed. |
| Title | METHODS FOR OPTOGENETIC MANIPULATION OF STOMATAL FUNCTION |
| Description | The invention relates to methods of increasing stomatal function in plants, which as a result leads to an increase in carbon assimilation and/or water use efficiency and ultimately an increase in yield. In particular the methods of the invention relate to the expression of light-gated potassium channels in the stomatal complex. Also described are genetically altered plants characterised by the above phenotype as well as methods of producing such plants. |
| IP Reference | WO2020169973 |
| Protection | Patent application published |
| Year Protection Granted | 2020 |
| Licensed | Yes |
| Impact | License to Plant Biosciences Ltd |
| Title | P53 PEPTIDE DISRUPTERS OF FOXO4:P53 PROTEIN BINDING, VARIANTS AND CONJUGATES THEREOF, AND ASSOCIATED METHODS OF MAKING AND USING THE SAME FOR CAUSING SENOLYSIS AND/OR TREATMENT OF AGE-RELATED DISEASES |
| Description | Ion channels are implicated in a wide range of physiological functions, including electrical signal transduction, chemical signaling, trans-epithelial transport, muscle contraction, hormone secretion, and regulation of ion concentrations, pH, and cell volume. Ion channel dysfunction has been associated with diseases in various tissues, such as pancreas, bone, kidney, central nervous system ("CNS"), heart, gastrointestinal system, and retina. Much of the ion channel family of proteins remains unexplored as drug targets. Thus, new methods and compositions that target ion channels or proteins thereof for the treatment and/or amelioration or prevention of ion-channel-related diseases and/or conditions are needed. |
| IP Reference | US20200262877A1 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | Commercial In Confidence |
| Impact | Led on from "STRUCTURE, MANUFACTURING AND USES OF HOXD12-PDE8A CELL-PENETRATING PEPTIDES," WO2020163771A1. |
| Title | STRUCTURE, MANUFACTURING AND USES OF HOXD12-PDE8A CELL-PENETRATING PEPTIDES |
| Description | Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions, including cancer and/or autoimmune diseases. In some embodiments, the conjugates and/or fusion proteins incorporate a homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins include a cAMP-degrading phosphodiesterase-8A (PDE8A) - C-Raf complex. In various embodiments, the disclosed compositions are suitable for delivery into a cell (i) the expression product of a gene of interest and/or (ii) novel peptides or polynucleotides to regulate gene function. |
| IP Reference | WO2020163771 |
| Protection | Patent application published |
| Year Protection Granted | 2020 |
| Licensed | Commercial In Confidence |
| Impact | Development of other IP, including US20200262877A1, "P53 PEPTIDE DISRUPTERS OF FOXO4:P53 PROTEIN BINDING, VARIANTS AND CONJUGATES THEREOF, AND ASSOCIATED METHODS OF MAKING AND USING THE SAME FOR CAUSING SENOLYSIS AND/OR TREATMENT OF AGE-RELATED DISEASES." |
| Title | THERAPEUTIC USES OF MICROVESICLES AND RELATED MICRORNAS |
| Description | The present invention provides improved methods and compositions based on microvesicles for the treatment of various diseases, disorders and conditions. In particular, the present invention encompasses the recognition that microvesicles contain specific microRNAs which may function as intercellular regulators involved in cell or tissue regeneration, remodeling, reconstruction, reprogramming or transdifferentiation. Thus, among other things, the present invention provides methods and compositions based on microvesicles and/or associated microRNAs that provide more predictable and effective therapeutic results. |
| IP Reference | US20190167732A1 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | Commercial In Confidence |
| Impact | N/A |
| Company Name | Epeius Pharma |
| Description | Epeius pharma develops next generation biological vehicles for delivery of therapeutic proteins into the central nervous system (CNS). Efficient and predictable therapeutic delivery is particularly challenging in neurological diseases due to the blood-brain barrier (BBB), which tightly regulates the transport of molecules to the brain, and blocks the transport of most large, charged and hydrophilic molecules, which are common features of therapeutic agents. The lack of efficient CNS delivery methods limits protein replacement therapy and remains to be one of the greatest unmet medical needs preventing successful treatment for debilitating neurological disorders. The developed technology will utilize a novel biological platform and apply cell and gene therapy approaches to overcome these challenges. This platform will enable the introduction of therapeutic proteins into the CNS thereby potentially treating and even reversing the devastating effects of neurodevelopmental and neurodegenerative diseases. Epeius pharma will focus on development of the novel drug delivery platform and its combination with several therapeutic candidates with an aim to be clinically tested and validated in relevant patient populations. Some of the clinical conditions to be targeted are orphan diseases with no alternative treatment methods available. |
| Year Established | 2019 |
| Impact | In development |
| Website | https://www.prweb.com/releases/futurx_together_with_ramot_at_tel_aviv_university_and_glasgow_univers... |
| Company Name | Solasta Bio |
| Description | Solasta Bio produces pest control products designed to selectively inhibit certain insects, using peptide technology designed to be more environmentally friendly than standard insecticides. |
| Year Established | 2020 |
| Impact | Solasta Bio is dedicated to discovery of new, more selective, "greener" insect control agents that are valuable for modern pest management approaches. Solasta's approach is based on development of short peptides that disrupt function in pest species, while leaving beneficial insects and vertebrates untouched. These compounds thus have high selectivity, low environmental impact, and low- or no residues. |
| Website | https://solastabio.com/ |
| Company Name | PPG (Glasgow) Limited |
| Description | |
| Year Established | 2017 |
| Impact | In development |
| Company Name | Keltic Pharma Limited |
| Description | |
| Year Established | 2021 |
| Impact | Several funding streams secured: £300K in kind funding from the European Lead Factory, EvoTec for in-kind funding of £350K, 5M EURO Venture Loan from the European Union Malaria Fund (EUMF), BMGF (funding = $500K) and by MMV (250K EUROs). |
| Description | Academic Researchers Legal Support |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | Opportunity Audit highlighted that their was a need for researchers to be supported and advised on the legal aspects of their work, such as when and why non-disclosure agreements and materials transfer agreements are needed. Storyboard animation style videos were produced giving researchers and students within the college the confidence to engage with collaborators and partners effectively. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.youtube.com/watch?v=Fg6n_MFw54g&t=16s |
| Description | Accurate models of the Sars-Cov2-virus |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | This collection of 49 models includes an accurate models of the Sras-Cov2-virus which was featured in the UKRI website (Getting to know the new coronavirus - Coronavirus: the science explained - UKRI). |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://coronavirusexplained.ukri.org/en/article/cad0010/ |
| Description | BBC 5 Live's Lunchtime Show, in which they discuss the GETAFIX trial testing favipiravir |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview for national news: https://youtu.be/Ab0jOE2Y4jE Dr Scott was interviewed by Naga Munchetty on the Wednesday 21 April 2021 edition of BBC 5 Live's Lunchtime Show, in which they discuss the GETAFIX trial testing favipiravir against Covid-19. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://youtu.be/Ab0jOE2Y4jE |
| Description | CVR Industry Workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | This project brought together CVR researchers and industry colleagues to begin knowledge exchange discussions. Through face-to-face interactions, to improve CVR researchers' understanding of industry needs, and raise awareness of CVR research opportunities with industry contacts. By improving understanding and raising awareness and to encourage and support new collaborations. As a direct result of this event, a formal collaboration was established between Dr Janet Scott and FUJIFILM Toyama Chemical Co., Ltd, underpinning the GETAFIX trial. Participation in this workshop also aided the establishment of a formal partnership between the CVR and LifeArc to create CVR CRUSH, a drug-screening facility for pre-clinical evaluation of SARS-CoV-2 therapeutics. 10.1186/s13063-020-04891-1 |
| Year(s) Of Engagement Activity | 2019 |
| Description | Explorathon 2020 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Prof. Tokatlidis' group participated in the Explorathon 2020 with two activities (i) via a 3 minute video on his groups research specifically aimed to address the general public. Two ECRS from the group were involved in this. (ii) a presentation of our group in the activity 'Fantastic proteins' that was organized by the Institute, as a follow up (for the third time) of this activity in previous Science Festivals |
| Year(s) Of Engagement Activity | 2020 |
| Description | Frontiers in Parasitology |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation given on 'Redox controlled functions of apicomplexan parasites are promising targets for drug discovery' |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://www.weizmann.ac.il/conferences/FIP2018/ |
| Description | GETAFIX trial testing favipiravir against Covid-19 |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview for national news: https://youtu.be/uFjfApyeQrk Dr Scott appeared on the Wednesday 21 April 2021 edition of BBC Scotland's The Nine to discusses the GETAFIX trial testing favipiravir against Covid-19. Speaking to presenter Martin Geissler about the antiviral drug that she hopes will be effective in treating Covid, Dr Scott said: "Favipiravir was first developed for influenza in Japan and we are hoping it will work for Covid-19." |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://youtu.be/uFjfApyeQrk |
| Description | How to create a sketchfab workflow - video |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | YouTube video on the workflow to create the Sketchfab page https://youtu.be/-tFdQj6n8W4 The video has had 300 views and the channel attracts around 16k views/month. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://youtu.be/-tFdQj6n8W4 |
| Description | INCISE Monthly Seminar Series |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Third sector organisations |
| Results and Impact | The INCISE partnership has been running a monthly seminar series since July 2020, explore the background behind the project. This has been well received by both Innovate UK and the larger academic community. |
| Year(s) Of Engagement Activity | 2020,2021 |
| Description | LinkedIn Live interview where a v2.0 of the gallery was discussed |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Third sector organisations |
| Results and Impact | In addition, a Virtual Reality Gallery using the 3D models was created and trialled in a VR Teaching lab at UofG (https://youtu.be/-tFdQj6n8W4 ). This led to a LinkedIn Live interview where a v2.0 of the gallery was discussed; (https://youtu.be/GgBuqM1l7tY) |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.youtube.com/watch?v=GgBuqM1l7tY |
| Description | Mitochondria Collective Webinar - Biochemical Society and the GSA |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Kostas Tokatlidis organized, together with the Biochemical Society and the GSA, a webinar on Mitochondria Collective, as part of the Biochemistry focus series of the Biochemical Society. This was in the context of the Mitochondria Awareness week 2021. A video recording of the webinar is available on the BioSoc and on the BioSoc youtube channel. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.youtube.com/watch?v=PcY6sb3tHkk |
| Description | Mitochondria and Us |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Third sector organisations |
| Results and Impact | Prof Tokatlidis has organised a webinar 'Mitochondria and Us' on mitochondria dysfunction and disease with the support of the Royal Society of Edinburgh, The Glasgow School of Art and the Lilly Foundation (the largest UK charity for mitochondrial disease). This was an international event of a global audience of more than 350 participants highlighting the interdisciplinary aspects of mitochondrial research, ECR involvement, social scientists and creative industry practitioners (artists and designers). One output of this event was the creation of a video by a designer/videographer around mitochondria research, mitochondria dysfunction, our work in Glasgow, and the event itself. Prof Tokatlidis also co-organised a Crossover workshop 'Mitochondria and Us' (funded by the RSE and the Biochemical Society) on the co-creation of interdisciplinary stories This workshop has invited a broad range of disciplinary expertise and interests to explore how to co-create stories at the societal, experiential and biochemical levels to provide greater understanding of people's experiences living with and working with mitochondrial diseases. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.youtube.com/watch?v=mmAyUv30zPI |
| Description | Prof. Kostas Tokatlidis - Lily Foundation family weekend |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | PPIE (Public patient involevement and engagement): Prof Tokatlidis was invited as a speaker in the Lily Foundation family weekend (the largest UK based mito-patient charity) alongside the RA Fara van der Schans. Prof Tokatlidis led 2 focused workshops in the meeting and Fara van der Schans another one. Disemination after this on social media channels (twitter of Tokatlidis Lab and the Lily Foundation); https://www.youtube.com/watch?v=mmAyUv30zPI ; https://www.youtube.com/watch?v=ejQaeEqDn7Y |
| Year(s) Of Engagement Activity | 2020,2021 |
| URL | https://www.youtube.com/watch?v=mmAyUv30zPI |
| Description | Prof. Kostas Tokatlidis - Mitotargin case study video |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Prof Kostas Tokatlidis (Cathcart Chair of Biochemistry, University of Glasgow) and Dr Keith Wreggett (Biotech Consultant, InnoSpective) discuss the Mitotargin Project; an innovative translational project to develop therapeutic and diagnostic applications through research into the mitochondria. Mitotargin Translational Project funded through the Wellcome Trust Translational Partnership Award, grant ref. 219390/Z/19/Z, BBSRC Impact Accelerator Account ref. BB/S506734/1, MRC Proximity to Discovery award ref. MC_PC_17190 and MRC Confidence in Concept Award, grant ref. MC_PC_18048 and MC_PC_19039. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.youtube.com/watch?v=1YJLB1nVnO4 |
| Description | UK Autophagy Network meeting Glasgow |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | The UK Autophagy Network meeting, held in Glasgow and organised by Dr. E. Kalkman (Institute of Cancer Sciences, University of Glasgow), focused on the scientific community around this theme to enhance knowledge and to promote novel cross-institute collaborations in the field. The organisation of a British UK Autophagy Network Conference gathers together the autophagy researchers across the United Kingdom and internationally help to further build this community. Considering the number of competing conferences around the time of our meeting it was a great turn-out. The total number of attendees registered for the meeting was 81, in addition to this we had company stands from Bio-Techne (1 person), BMG Labtech (2 people), Cambridge Bioscience (1 person), Miltenyi Biotec (1 person), Promega (2 people), and Sartorius (1 person). This brought the total number of people at the meeting to 89. The split was 76 people from within the UK (10 of which from the University of Glasgow), and 5 attendees coming from abroad. However, the actual nationalities of the attendees must have easily exceeded 10. Most of the attendees were academic researchers, but there were one or two people from companies. One person came from the company LifeArc with which the Helgason group has an active drug discovery collaboration. Feedback from attendees as well as company representatives was overwhelmingly positive. The received funding and sponsoring was acknowledged at the start of the meeting as well as in the meeting wrap up presentation. |
| Year(s) Of Engagement Activity | 2019 |